Recent launches of new active substances (NAS) and a strong R&D pipeline indicate that recent global drug development not only has been robust, but also is poised for even stronger growth over the coming decade, according to a study recently completed by the Tufts Center for the Study of Drug Development.
"The global outlook for drug development is as strong—and perhaps stronger—than ever, and while the U.S. continues to be the world leader, as measured by the number of patent awards, clinical trials, and product launches, the landscape is changing," said Christopher-Paul Milne, research associate professor and director of research at Tufts CSDD at Tufts University School of Medicine, who conducted the analysis.
He added, "As populations outside the U.S., Europe, and Japan become more affluent, and as demand for specific therapies shifts, new and emerging developers will step in to serve those growing markets."
China, India, and South Korea, which have focused heavily on vaccine development to date, are becoming ever more important players in global R&D, Milne noted, while the lack of significant development infrastructure, among other factors, has stymied NA...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).